Table 5.

Net reclassification for model improvement with addition of plasma neutrophil gelatinase-associated lipocalin (pNGAL) and serum Cystatin C (SCysC)

AKI (21.1%)	+pNGAL	pNGAL + SCysC
Goodness-of-fit reference	0.628	0.961
Goodness-of-fit reference + B	0.961	0.921
AUC of reference	0.75 (0.70–0.80)	0.84 (0.80–0.88)
AUC of reference + B	0.84 (0.80–0.88)	0.87 (0.81–0.90) =0.002
P value (AUCs difference)	<0.001
cfNRI, % (CI)
cfNRI events	52.4 (29.4 to 69.4)	40.3 (25.5 to 56.8)
cfNRI nonevents	41.9 (33.4 to 58.3)	55.7 (43.0 to 68.9)
cfNRI	94.3 (76.7 to 112.4)	96.1 (74.8 to 119.0)
IDI (CI)
IDI events	0.10 (0.06 to 0.15)	0.10 (0.04 to 0.18)
IDI nonevents	0.03 (0.01 to 0.04)	0.03 (0.01 to 0.05)
IDI	0.12 (0.07 to 0.19)	0.12 (0.05 to 0.22)

The reference is the multiple regression model with age, cardiovascular disease, and susceptibility now improved with pNGAL and SCysC at T12 study time. Hosmer–Lemeshow goodness-of-fit test was used to study the calibration of the model. B, biomarker; AUC, area under the receiver operator characteristic curve; cfNRI, category-free net reclassification improvement (cfNRI events + cfNRI nonevents); CI, 95% confidence interval; IDI, integrated discrimination improvement.